Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study

Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study

Abstract Background Tumor necrosis factor-alpha (TNF) is an inflammatory cytokine implicated in the development of many chronic inflammatory diseases and TNF-α inhibitors (TNF-I) are frequently prescribed as treatment. Their malignancy risk is debated, with pro-oncogenic effects of decreased immune...

Full description

Saved in:
Bibliographic Details
Main Authors: Conor B. Driscoll, Jordan M. Rich, Christopher Yang, Joseph Nicolas, Dylan Isaacson, Philip Silberman, Xinlei Mi, Sai Kaushik Shakar Ramesh Kumar, Hui Zhang, Steven Belknap, William H. Temps, Edward M. Schaeffer, Shilajit D. Kundu
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Inflammation
Subjects:
Cancer
Neoplasm
Malignancy
Tumor necrosis factor alpha inhibitors
Inflammation
Immunosuppression
Online Access:https://doi.org/10.1186/s12950-025-00445-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12950-025-00445-x

Similar Items